Skip to main content
SpringerLink
Log in

MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66(6):443–459. https://doi.org/10.3322/caac.21357

    Article  Google Scholar 

  2. Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B (2017) Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129(5):553–560. https://doi.org/10.1182/blood-2016-01-689422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Thompson PA, Ravandi F (2017) How I manage patients with hairy cell leukaemia. Br J Haematol 177(4):543–556. https://doi.org/10.1111/bjh.14524

    Article  CAS  PubMed  Google Scholar 

  4. Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ (2013) Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res 19(22):6313–6321. https://doi.org/10.1158/1078-0432.CCR-13-1848

    Article  CAS  PubMed  Google Scholar 

  5. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370(12):1101–1110. https://doi.org/10.1056/NEJMoa1313984

    Article  CAS  PubMed  Google Scholar 

  6. Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD (2016) Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17(8):1081–1093. https://doi.org/10.1016/S1470-2045(16)30097-3

    Article  CAS  PubMed  Google Scholar 

  7. Bohn JP, Willenbacher E, Steurer M (2016) Obinutuzumab in multidrug-resistant hairy cell leukemia. Ann Hematol 95(2):351–352. https://doi.org/10.1007/s00277-015-2520-y

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX, 75390, USA

    Navid Sadeghi & Hsiao C. Li

Authors
  1. Navid Sadeghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hsiao C. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Navid Sadeghi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sadeghi, N., Li, H.C. MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab. Ann Hematol 97, 723–724 (2018). https://doi.org/10.1007/s00277-017-3219-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3219-z

Search

Navigation